Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxalisib in FCD-II, TSC, or HME
NCT07287202Phase 2Recruiting
- Sponsor
- SoVarGen
- Start
- Jul 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paxalisib in focal cortical dysplasia type II (FCD-II), tuberous sclerosis complex (TSC) and hemimegalencephaly (HME) (2 arms), sponsored by SoVarGen. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 12 weeks. Started Jul 2026; status: recruiting.
02
Drugs
paxalisib
03
Conditions
focal cortical dysplasia type II (FCD-II)tuberous sclerosis complex (TSC)hemimegalencephaly (HME)
Beyond the preview
Go deeper on NCT07287202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287202.